(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
ZOSANO PHARMA CORPORATION | |||||||||||||||||
Date: January 5, 2022 | By: | /s/ Christine Matthews | |||||||||||||||
Name: Christine Matthews | |||||||||||||||||
Title: Chief Financial Officer |
Cover Page |
Nov. 17, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jan. 05, 2022 |
Entity Registrant Name | ZOSANO PHARMA CORPORATION |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36570 |
Entity Tax Identification Number | 45-4488360 |
Entity Address, Address Line One | 34790 Ardentech Court |
Entity Address, City or Town | Fremont |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94555 |
City Area Code | 510 |
Local Phone Number | 745-1200 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value |
Trading Symbol | ZSAN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001587221 |
-8?20$3;8T.P
M6BP^0"X99K>]9!:G
A/MR^$1)S,N0RD;P!?67J:SW8DEX)WEM"$@A(N'+M^;$
MB8HV33.A:H$<+U+DY'MB0A6!*FZFE]*G^HKFLG/UMAV).C&,#4I2<1%F\!S@
M#XM]N0?*?%]>VB,KRU>N<);RK$B.X_>'NI:7G>ZP>^-=Y=7+N1&ZYNJ]*79?
MB0&N77@_28JA5E,1,7FFX 5?LOULX:>1HJ\5>M5Y;;>7[7;8%?X#V#;,"6@O6,=RL >-WH7@Z;X Y>$
M/6EN%X9];^APUSG]H;.W8IYG7.8N=U+7VX_H["QU>?]9*?OO@6ZFUF7;YVYJ
M)=YPMU/KTJC<3ZUMT/YL^ISI8C^$MHJ*2]4/\_F=SBZ+AVJR3\;8
MJ_>S?$@#CXQW+^]:(>]J2H\JL+>+P0J#:[+KM<+Y/;W+1Z5PF,!G ?>!"JV9
MA., ,!CZ("R>NXM8Y.O(>;=_;HPC 5 @VF@)Z1&I3$X[LT"7D8B_D% V8 ], 1D8*3,$D5<9I$(++(U5 V]49@=3+D
MB7P&*[0BGWP@U"$WXDBK9&A(WNF)XQEZ(TJ$FEM:HT
M*;NH:]6^308.Q"K8S#9-VE]?VP&EI)
U( LYT+L%F'.'P]"/46R1[PCCWV3SD7VEFQ
MDE[6MHR78BLP(IM$.F1R">6P0"^VXI5Q<:^4RER*^B^S15HI6I":@7J^4<[
M2D(Y]^Q>X6&"?]
C+QD'J16]JL3_27TX>F$X:DD80S%H5P8.
M4P JT]_E?^=QHOTIYI1!0ZQO(:> ,&T $P$&*(04A9A% M).JU+KO8P-_\U5
ME^6!5XCU/B5=-WE4C&VY.M75KH'7IYR=ZKY&5>?$H5:I*K%_SCI577J-*U6U
MC;OB_R&1:7:;9N4$M]PN)7GVN-@93;%$?A ".X$0@"!:/'"O" B*)QL"
M[=MK!.?[PP[]C;0D5#2O[69:*N_T&/!NWUWKQ,'<'*9B]#*R0_%PLJ=W&=G=
MR\ %Q2GE[=+B]K:N1>;=C